Donghua Zhao, Jian Peng, Zhongbo Xiao, Feifei Zhang, Xinhui Peng, Hao Yang, Fuqiang Liu, Yan Li, Yong Xie, Xinfu Huang, Surong Meng, Muli Wu, Dingli Xu
Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
J Interv Card Electrophysiol. 2013 Jan;36(1):27-32; discussion 32. doi: 10.1007/s10840-012-9727-9. Epub 2012 Oct 23.
Tachycardia-induced cardiomyopathy (TCM) is a reversible cause of heart failure. Little is known of the characteristics of tachycardia associated with the development of left ventricular (LV) dysfunction and the reversal of cardiomyopathy after cure of tachycardia. This study aimed to examine the reversal of cardiomyopathy in patients undergoing ablation with congestive heart failure secondary to tachycardia.
A total of 625 patients underwent radiofrequency ablation for tachycardiarrhymias between January 2009 and July 2011. Echocardiography analysis was performed to identify patients with depressed LV function, defined as a left ventricular ejection fraction <50 %. Patients with preexisting structural heart disease (n = 10) were excluded. NT-pro-B-type natriuretic peptide (NT-proBNP) assessment was performed before ablation in patients considered to have TCM (n = 17). Repeated echocardiography study and NT-proBNP assessment were measured after a mean follow-up of 3 months. Levels of NT-proBNP before and after ablation were compared. Reversal of cardiomyopathy was also assessed.
The incidence of TCM was 2.7 % (12 males; age, 35.8 ± 17.1 years). Successful ablation was performed in 16 of 17 patients (94.1 %). There was a significant improvement in left ventricular ejection fraction (36.7 ± 7.5 vs. 59.4 ± 9.7 %; P < 0.001). The mean left ventricular end-diastolic diameter before treatment was 59.5 ± 8.3 mm (range, 43 to 70), compared with 51.9 ± 7.4 mm (range, 40 to 67) (P = 0.009) after 3 months follow-up. The levels of NT-proBNP decreased after ablation procedure, from 4,092.6 ± 3,916.6 to 478.9 ± 881.9 pg/ml (P < 0.001). After successful ablation, ventricular function normalized in 15 of 17 (88.2 %) patients at a mean of 3 months.
Restoration of LV function and reversal of LV remodeling can be achieved with successful elimination of tachycardia in the majority of patients. NT-proBNP level elevates in subjects with TCM and decreases sharply after ablation.
心动过速性心肌病(TCM)是心力衰竭的一个可逆病因。对于与左心室(LV)功能障碍发展相关的心动过速特征以及心动过速治愈后心肌病的逆转情况,人们了解甚少。本研究旨在探讨因心动过速继发充血性心力衰竭而接受消融治疗的患者中心肌病的逆转情况。
2009年1月至2011年7月期间,共有625例患者接受了心律失常的射频消融治疗。进行超声心动图分析以识别左心室功能降低的患者,左心室功能降低定义为左心室射血分数<50%。排除已有结构性心脏病的患者(n = 10)。对被认为患有TCM的患者(n = 17)在消融术前进行N末端B型利钠肽原(NT-proBNP)评估。在平均随访3个月后进行重复的超声心动图研究和NT-proBNP评估。比较消融前后NT-proBNP的水平。还评估了心肌病的逆转情况。
TCM的发生率为2.7%(12例男性;年龄,35.8±17.1岁)。17例患者中有16例(94.1%)成功进行了消融。左心室射血分数有显著改善(36.7±7.5%对59.4±9.7%;P < 0.001)。治疗前左心室舒张末期内径的平均值为59.5±8.3mm(范围,43至70),随访3个月后为51.9±7.4mm(范围,40至67)(P = 0.009)。消融术后NT-proBNP水平降低,从4,092.6±3,916.6降至478.9±881.9pg/ml(P < 0.001)。成功消融后,17例患者中有15例(88.2%)的心室功能在平均3个月时恢复正常。
在大多数患者中,成功消除心动过速可实现左心室功能的恢复和左心室重构的逆转。TCM患者的NT-proBNP水平升高,消融后急剧下降。